tirzepatide by lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity FDA approval for Zepbound (tirzepatide)

Participants taking tirzepatide lost approximately 20 percent of their body weight on average over 72 weeks, while those using semaglutide, also known as Ozempic or Wegovy, lost about 14 percent

The clinical expert also noted that they are more comfortable prescribing GLP-1 agonists than naltrexone-bupropion as the latter has more drug interactions and side effects, and because a cardiovascular safety study was never completed for this combination

Eat Enough Protein: GLP-1 drugs often blunt your appetite, which can be a double-edged sword

However, several considerations merit attention

For convenience and needle aversion : Oral GHK-Cu is the easiest option, but understand that systemic benefits will be significantly limited by poor bioavailability